CA2457624A1 - Nutrient therapy for immuno-compromised patients - Google Patents

Nutrient therapy for immuno-compromised patients Download PDF

Info

Publication number
CA2457624A1
CA2457624A1 CA002457624A CA2457624A CA2457624A1 CA 2457624 A1 CA2457624 A1 CA 2457624A1 CA 002457624 A CA002457624 A CA 002457624A CA 2457624 A CA2457624 A CA 2457624A CA 2457624 A1 CA2457624 A1 CA 2457624A1
Authority
CA
Canada
Prior art keywords
sod
nutritional supplement
component
group
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002457624A
Other languages
English (en)
French (fr)
Inventor
Carl Germano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Biotechnologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2457624A1 publication Critical patent/CA2457624A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
CA002457624A 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients Abandoned CA2457624A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/927,174 US6503506B1 (en) 2001-08-10 2001-08-10 Nutrient therapy for immuno-compromised patients
US09/927,174 2001-08-10
PCT/US2002/025358 WO2003013438A2 (en) 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients

Publications (1)

Publication Number Publication Date
CA2457624A1 true CA2457624A1 (en) 2003-02-20

Family

ID=25454328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002457624A Abandoned CA2457624A1 (en) 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients

Country Status (9)

Country Link
US (1) US6503506B1 (cg-RX-API-DMAC7.html)
EP (1) EP1432436A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005501061A (cg-RX-API-DMAC7.html)
CN (1) CN1568196A (cg-RX-API-DMAC7.html)
AP (1) AP2004002994A0 (cg-RX-API-DMAC7.html)
CA (1) CA2457624A1 (cg-RX-API-DMAC7.html)
EA (1) EA006439B1 (cg-RX-API-DMAC7.html)
OA (1) OA12649A (cg-RX-API-DMAC7.html)
WO (1) WO2003013438A2 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
FR2822704B1 (fr) * 2001-03-29 2005-02-18 Chiesi Sa Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
WO2005032278A1 (en) 2003-09-29 2005-04-14 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
ITTO20030789A1 (it) * 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
ES2677868T3 (es) * 2003-10-16 2018-08-07 Nestec S.A. Composición nutricional frente a los efectos secundarios de la quimioterapia o de la radioterapia
HRP20130459T1 (en) 2004-01-22 2013-06-30 University Of Miami Topical co-enzyme q10 formulations and methods of use
KR20060132667A (ko) * 2004-01-28 2006-12-21 네스텍소시에테아노님 피부 상태 개선 및 피부 질환 예방을 위한 영양 조성물
US20050209170A1 (en) * 2004-03-18 2005-09-22 Takemoto Arnold C Breast health preparations
EP1734978A2 (en) * 2004-03-17 2006-12-27 Arnold C. Takemoto Tissue detoxification and health supplements and methods of making and using them
JP2005336176A (ja) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd 肉体疲労改善剤
EP1600061B1 (en) * 2004-05-25 2010-05-12 Cognis IP Management GmbH Oral and/or topical compositions
US20050265990A1 (en) * 2004-06-01 2005-12-01 Shawn Talbott Treatments and nutritional supplements for assisting post-exercise recovery
JP5069000B2 (ja) * 2004-06-30 2012-11-07 敦生 関山 非炎症性ストレス応答の指標剤およびその利用
KR100584891B1 (ko) 2004-08-13 2006-05-30 (주)씨스팜 경구용 슈퍼옥사이드 디스뮤타제 제제인, 캔털루프 멜론추출물과 글리아딘 결합물을 숙취해소에 사용하는 방법
US7284385B2 (en) * 2004-09-16 2007-10-23 Hess Spencer W Pre-dried air reactivation for diesel fuel heated dessicant reactivator
JP5040060B2 (ja) * 2004-10-14 2012-10-03 大正製薬株式会社 メチオニン配合内服液剤
US20060147550A1 (en) * 2004-12-30 2006-07-06 Gorsek Wayne F Immune system enhancement and stimulation formulation
US20070114476A1 (en) * 2005-11-04 2007-05-24 Williams Christopher P Low radiocarbon nucleotide and amino acid dietary supplements
CN101316582A (zh) * 2005-11-30 2008-12-03 雀巢技术公司 治疗肌肉损失的方法
WO2007077995A1 (ja) * 2006-01-05 2007-07-12 Kyowa Hakko Kogyo Co., Ltd. 筋肉増量剤
GB0603975D0 (en) * 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
CN101420973A (zh) * 2006-03-15 2009-04-29 埃索谢尔制药公司 包含SODs和基于谷醇溶蛋白的肽片段的药物组份
FR2899065B1 (fr) * 2006-03-29 2008-07-18 Alain Dreyer Brevets Et Dev So Sod micro encapsulee et adsorbee sur support mineral et vegetal destinee a l'alimentation animale
DE102006046960A1 (de) * 2006-10-04 2008-04-10 Euro Allianz Pharma Gmbh Gesundheitsfördernde Nahrungsmittelzusammensetzung
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
EP2158462A4 (en) 2007-05-03 2010-05-05 Radiocarb Genetics Inc FOOD SUPPLEMENTS WITH LITTLE RADIO CARBON AND MANUFACTURING METHOD THEREFOR
ES2675942T3 (es) * 2007-09-27 2018-07-13 Biothera, Inc. Tratamiento con B-glucano de síntomas de infección del tracto respiratorio superior y del bienestar psicológico
WO2009099444A1 (en) * 2008-02-08 2009-08-13 Millennium Biotechnologies, Inc. Nutritional formula for athletes' recovery
JP6058263B2 (ja) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー 癌細胞においてアポトーシスを誘導する方法および使用
WO2010053854A1 (en) * 2008-11-06 2010-05-14 Altman Enterprises Llc Medication and treatment for disease
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
EP2311449A1 (de) * 2009-10-14 2011-04-20 NÖM Aktiengesellschaft Oral verabreichbare nahrungsergänzende Zusammensetzung enthaltend Carnitin
CN113142581B (zh) 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
WO2012097061A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
US9198881B2 (en) 2011-01-18 2015-12-01 Stephen T. Sinatra Equine nutritional supplement
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
MX381399B (es) 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN105709212A (zh) * 2016-01-29 2016-06-29 周瑞华 一种免疫平衡调节剂及其制备方法和应用
RU2656544C1 (ru) * 2017-07-07 2018-06-05 Общество с ограниченной ответственностью "Академия-Т" Функциональный продукт питания для коррекции психофизиологического состояния и нейромышечной передачи у спортсменов
CA3109188A1 (en) * 2018-08-10 2020-02-13 Maine Natural Health Company, Inc. Comestible compositions for promoting atp synthesis
CN110664824B (zh) * 2019-08-09 2021-01-01 北京佳博泰和健康科技有限公司 一种营养支持剂及其制备方法和用途
CN111820330A (zh) * 2020-07-17 2020-10-27 禹城保立康生物饲料有限公司 一种提高哺乳仔猪发育的母猪饲料
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
IT1258491B (it) * 1992-09-24 1996-02-26 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
FR2729296B1 (fr) 1995-01-12 1997-03-28 Europlanaire Compositions pharmaceutiques comprenant une superoxyde dismutase
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients

Also Published As

Publication number Publication date
EP1432436A2 (en) 2004-06-30
EA006439B1 (ru) 2005-12-29
EA200400291A1 (ru) 2004-08-26
AP2004002994A0 (en) 2004-03-31
OA12649A (en) 2006-06-16
WO2003013438A2 (en) 2003-02-20
US6503506B1 (en) 2003-01-07
JP2005501061A (ja) 2005-01-13
CN1568196A (zh) 2005-01-19
WO2003013438A3 (en) 2003-06-19
EP1432436A4 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
US6503506B1 (en) Nutrient therapy for immuno-compromised patients
EP1439831B1 (en) Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
EP1455603B1 (en) Stimulation of in vivo production of proteins with formulation comprising leucine
US6262019B1 (en) Method of treatment of glutathione deficient mammals
CA1333471C (en) Whey protein concentrate as food supplement
US5230902A (en) Undenatured whey protein concentrate to improve active systemic humoral immune response
US9956255B1 (en) Method to reduce body weight, fat accumulation and adipocyte size using Parabacteroides goldsteinii
US20200155589A1 (en) Composition For Enchanced Recovery After Surgery (ERAS)
Kadam et al. Health benefits of whey: A brief review
EP1748705B1 (en) Use of beta-cryptoxanthin
WO2011096413A1 (ja) 運動機能改善剤
EP2408320A1 (en) Kit of parts comprising l-glutamine and egcg
JP5394644B2 (ja) アスペルロシドまたはその類縁体を含む筋肉増強剤
CN106036387A (zh) 超级藜麦儿童生长营养包
AU2002324659A1 (en) Nutrient therapy for immuno-compromised patients
HK1073261A (en) Nutrient therapy for immuno-compromised patients
Cribb Whey proteins and immunity
WO2025213012A1 (en) Gummy nutritional product and method
WO2004000044A1 (en) Low-energy-diet
HK1065447B (en) Stimulation of in vivo production of proteins with formulation comprising leucine
JPS60237024A (ja) 肥満抑制組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued